RGTLF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EDT
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.15
Previous CloseN/A
Volume17.00
Average Volume (3M)0.00
Market Cap
$2.68M
Enterprise Value$12.72
Total Cash (Recent Filing)$1.53M
Total Debt (Recent Filing)$8.91M
Price to Earnings (P/E)―
Beta-1.47
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding116,609,580
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.33
Price to Sales (P/S)19.37
P/FCF Ratio-0.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash BurnThe reduction in operating cash outflow provides a limited improvement in near-term funding pressure. If maintained, better cash discipline could extend liquidity and reduce the pace of external financing needs, although operations remain far from self-funding.
Prior Gross ProfitPositive gross profit in prior years indicates the company has previously generated revenue above direct costs. That history may provide a base for recovery if products regain commercial traction, though the latest reversal shows this advantage is not currently secure.
Historical Equity CushionEarlier positive equity demonstrates that the company has previously maintained a balance-sheet cushion for shareholders and creditors. This historical capacity could support a recovery narrative, but rebuilding that cushion would require sustained profitability or new capital.
Bears Say
Revenue And Profit CollapseThe sharp revenue contraction and move into negative gross profit indicate that the current commercial base is not supporting the cost structure. Deep operating and net losses weaken reinvestment capacity and make a durable earnings recovery dependent on substantial business improvement.
Stressed Balance SheetNegative equity and debt materially exceeding the asset base indicate a thin financial cushion and elevated balance-sheet stress. This reduces flexibility to fund development or absorb setbacks, while increasing reliance on refinancing or additional capital.
Persistent Cash BurnRepeated negative operating and free cash flow show that the business has not demonstrated self-funded operations. Continued cash burn can constrain product development and commercialization, increase dependence on external funding, and dilute financial flexibility over coming quarters.
Argent Biopharma News
RGTLF FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is $2.68M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Mar 03, 2027 which is in 177 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -$0.027 earnings per share for the quarter.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 116,609,580 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -$0.027 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in RGTLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
RGTLF Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Argent Biopharma
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―